Paradigm Biocapital Advisors »

Moonlake Immunot shares owned by Paradigm Biocapital Advisors

Quarter-by-quarter ownership of Moonlake Immunot (MLTX) shares owned by Paradigm Biocapital Advisors from 13F filings

Historical chart of Paradigm Biocapital Advisors investment in Moonlake Immunot

Tip: Access up to 7 years of quarterly data

All positions including Moonlake Immunot held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Moonlake Immunot by Paradigm Biocapital Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $47M 932k 50.42
2023-06-30 $19M 370k 51.00

More positions owned by Paradigm Biocapital Advisors

Nuvalent Inc-a (NUVL)
Arcellx Common Stock Call Option (ACLX)
Argenx Se Sponsored Adr (ARGX)
Revolution Medicines (RVMD)
Crinetics Pharmaceuticals In (CRNX)
Merus N V (MRUS)
Janux Therapeutics (JANX)
Vaxcyte Call Option (PCVX)
Kura Oncology (KURA)
Tarsus Pharmaceuticals (TARS)
Edgewise Therapeutics (EWTX)
Disc Medicine (IRON)
Miragen Therapeutics (VRDN)
Olema Pharmaceuticals (OLMA)
Arvinas Ord (ARVN)

View all positions for Paradigm Biocapital Advisors

Top funds holding Moonlake Immunot

BVF
Cormorant Asset Management
T. Rowe Price Associates
Citadel Advisors
Holocene Advisors
Goldman Sachs Group
Westfield Capital Management Company
Marshall Wace
Federated Investors
Alliancebernstein
Paradigm Biocapital Advisors
Logos Global Management
Fred Alger Management
Balyasny Asset Management
Nuveen Asset Management

View all funds holding Moonlake Immunot